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Abstract
The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple cancers and has bolstered
interest in this treatment approach. So far, emerging clinical data show limited clinical efficacy of these agents in
ovarian cancer with objective response rates of 10–15% with some durable responses. In this review, we present
emerging clinical data of completed trials of immune checkpoint inhibitors and review ongoing studies. In
addition we examine the current knowledge of the tumor microenvironment of ovarian cancers with a focus
on the significance of PD-L1 expression and tumor-infiltrating lymphocytes on predicting response to immune
checkpoint blockade. We evaluate approaches to improve treatment outcomes through the use of predictive
biomarkers and patient selection. Finally, we review management considerations including immune related
adverse events and response criteria.
Keywords: Ovarian cancer, Fallopian tube cancer, Primary peritoneal cancer, Immunotherapy, Immune
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Background
Role of immune checkpoints and development of immune
checkpoint inhibitors
Ovarian cancer is the most lethal of the gynecologic ma-
lignancies. Over 22,000 new cases of ovarian cancer are
diagnosed each year in the United States resulting in
greater than 14,000 deaths per year [1]. The five year
survival rate is less than 25% for women diagnosed with
advanced stage disease (stage III or IV) despite aggres-
sive treatment with surgery and adjuvant chemotherapy.
Although >80% of patients will have a response to initial
therapy, epithelial ovarian cancer ultimately recurs in
the majority of patients. Recurrence is associated with a
poor prognosis because of the eventual development of
chemotherapy-resistant disease. Thus there is a great
need, and opportunity, to improve ovarian cancer out-
comes by understanding the immune milieu of ovarian
cancers and harnessing the power of immunotherapy.
This review will focus on the current understanding
of the immune microenvironment of ovarian cancers
and the potential role for immunotherapy in the treatment
of this disease.
Immunotherapy refers to treatment designed to en-
hance an individual’s own immune function to eradicate
malignant cells. While there have been various ap-
proaches, from cancer vaccines to adoptive immune cell
therapies, immune checkpoint inhibitors have caused a
paradigm shift in cancer treatment. These therapies are
now FDA-approved for a variety of cancers including
melanoma, non-small cell lung cancer (NSCLC), renal
cell carcinomas (RCC), bladder cancer, and classical
Hodgkin lymphoma. The enthusiasm for this approach
stems from evidence of complete and long-lasting tumor
regression in malignancies that are often refractory to
chemotherapy.
T-cell mediated cancer cell death requires the produc-
tion of effector T-cells (Teff ) through the coordinated
initiation of a multi-step process involving antigen pres-
entation, priming and activation, T-cell trafficking and
infiltration into the tumor, recognition of cancer cells,
and cancer cell elimination [2]. This T-cell mediated im-
mune response is regulated by a number of stimulatory
and inhibitory signals. Inhibitory signals serve to prevent
pathologic over-activation of the immune system, as an
uncontrolled inflammatory response could result in the
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development of autoimmune or inflammatory disorders.
However, inhibition of the Teff response against cancer
cells contributes to immune evasion. These inhibitory
signals may come from extrinsic sources, such as regula-
tory T-cells (Tregs) and inhibitory cytokines, or intrinsic
sources, such as immune checkpoint proteins expressed
on the surface of Teff. It is the balance of these signals
that determines the success or failure of the immune
system to eliminate cancer cells.
Tregs play a critical role in the extrinsic suppression of
anti-tumor immunity. When Tregs are the dominant T-
cell population in the tumor microenvironment, they
inhibit tumor-antigen specific immunity and promote
tumor growth. Depletion of these Tregs can restore anti-
tumor immune activity. Similarly, other suppressive
immune cells [e.g. myeloid derived suppressor cells
(MDSCs), M2 macrophages] influence the balance of
regulatory signals.
Immune checkpoint receptors, such as cytotoxic T
lymphocyte-associated protein 4 (CTLA-4) and pro-
grammed cell death protein 1 (PD-1), have emerged as
critical intrinsic modulatory mechanisms impairing nat-
ural anti-neoplastic immunity (Fig. 1). These receptors
are negative regulators which attenuate normal T-cell
activation to prevent pathologic over-activation. Interfer-
ing with immune checkpoint signaling has been shown
to enhance anti-tumor immune responses through the
recovery of T-cell function. The CTLA-4 and PD-1 im-
mune checkpoint proteins function at different points in
the process, which may explain their differential activ-
ities and toxicities. The CTLA-4 immune checkpoint
regulates T-cell priming and activation, activities that
occur in the early phases of the immune response. Inhib-
ition of CTLA-4 during the T-cell priming/ activation step
leads to dysregulated expansion of auto-reactive T cells,
including tumor-specific T-cells. Anti-CTLA-4 inhibitors
have been associated with significant immune-related tox-
icities which are likely a result of the indiscriminate and
unselected activation of auto-reactive T-cells.
PD-1 is a cell surface receptor that is upregulated dur-
ing normal T-cell activation and modulates the activity
of antigen-experienced effector T-cells. Interaction of
PD-1 with either of its two known ligands, PD-L1 and
PD-L2, results in inhibition of T-cell signaling and cyto-
kine production as well as decreased effector T-cell
numbers due to limited T-cell proliferation and in-
creased susceptibility to apoptosis. Of the two ligands,
PD-L1 appears to be the more relevant in the tumor
microenvironment and is expressed on a wide range of
tumor cells. Tumor-infiltrating lymphocytes can induce
PD-L1 expression on tumor cells leading to reduced
anti-tumor immunity [3]. PD-L1 expression may also be
regulated through gene amplification or via oncogenic
signaling pathways [4–6]. Antibodies directed at either
PD-1 or PD-L1 result in abrogation of the negative
signal, thus restoring T-cell function.
An important distinction between CTLA-4 and PD-1/
L1 inhibitors is their location of action [7]. Because
CTLA-4 regulates T-cell priming and activation, anti-
CTLA-4 antibodies lead to activation of T-cells in
lymphoid peripheral tissues. Anti-PD-1/L1 effects appear
to be limited to the tumor microenvironment without
Fig. 1 Costimulatory and coinhibitory pathways regulate the T-cell response to antigen. APC: antigen-presenting cell, CTLA-4: cytotoxic T
lymphocyte-associated protein 4, MHC: major histocompatibility complex, PD-1: programmed cell death protein 1; PD-L1: PD-1 ligand, TCR:
T-cell receptor
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evidence of recirculation. Thus a number of pharmacody-
namic markers for anti-CTLA-4 activity have been identi-
fied in the peripheral blood, whereas no biomarkers of
PD-1 activity have been isolated from peripheral blood
thus far.
Evidence for using checkpoint inhibitors in ovarian cancer
Two central tenets have emerged to predict effective
treatment with immune checkpoint inhibitors: 1) acces-
sibility of the tumor by effector immune cells and 2)
dominance of the immune checkpoint pathways as the
mechanism suppressing anti-tumor immunity. The first
is frequently defined by the presence of tumor-
infiltrating lymphocytes or the ratio of effector immune
cells [i.e. Teff, dendritic cells (DCs), M1 macrophages] to
immune suppressive immune cells [i.e. Tregs, myeloid
derived suppressor cells (MDSCs), M2 macrophages].
The second principle is less well defined as no accurate
biomarker has been identified, although multiple ap-
proaches are being evaluated. Expression of PD-L1 on
tumor cells has been suggested as a predictive biomarker
to identify cancers that may be more responsive to PD-1/
PD-L1 inhibitors [8]. Based on work initially performed in
melanomas, tumors have been classified into 4 groups
based on the presence of tumor-infiltrating lymphocytes
(TILs) and PD-L1 expression (Table 1) [3, 9]. Type I tu-
mors exhibit a pattern of adaptive immune resistance and
may be most likely to respond to immune checkpoint in-
hibitors. Conversely, Type II tumors show no discernable
immune reaction and single agent checkpoint blockade is
unlikely to be successful. Alternative approaches that in-
clude methods to recruit effector immune populations to
the tumor (e.g. vaccines), possibly in combination with
immune checkpoint inhibitors, are predicted to be
necessary. Type III tumors exhibit intrinsic expression of
PD-L1, possibly through oncogenic stimulation, with no
immune reactivity. This highlights that tumor expression
of PD-L1 alone cannot be used as an indicator of potential
benefit of PD-1/L1 inhibition as without effector immune
cells in the tumor, single agent immune checkpoint inhib-
ition is unlikely to be beneficial. Similar to type II tumors,
approaches to stimulate immune trafficking to the tumor
will be necessary. Finally Type IV tumors display a pattern
of tolerance to immune infiltration that is not dependent
on PD-L1 expression. Thus, other suppressive signals
are likely present and inhibition of other checkpoint re-
ceptors may be beneficial. Although this stratification
system is based on studies in melanoma and presents
several caveats (ref. [9]), it provides a framework for
understanding the tumor microenvironment and ra-
tionale for the benefit of immune checkpoint inhibitors
in ovarian cancer.
Prognostic significance of ovarian cancer tumor
microenvironment
Evidence of the importance of the local tumor immune
microenvironment in ovarian cancer emerged in 2003
when Zhang et al. showed that infiltration of treatment
naïve tumors with T-cells was associated with a signifi-
cantly improved median progression free (22.4 vs
5.8 months, p < 0.001) and overall survival (50.3 vs
18.0 months, p < 0.001) compared to tumors with no T-
cells present [10]. However, we have since learned that
not only is presence of T cells important, but that the
type of T-cell present influences outcomes. The propor-
tion of Tregs in the tumor negatively impacts clinical out-
comes and was a predictor of increased risk of death in
a multi-variate analysis [11, 12]. Multiple studies have
since confirmed that the ratio of immune suppressive to
effector immune infiltrates within ovarian tumors is as-
sociated with clinical outcome [13–17]. Immune re-
sponses to ovarian cancer appear to vary by histologic
subtype with high-grade serous cancers most likely asso-
ciated with a prognostically favorable tumor-infiltrating
lymphocyte response [18, 19]. Classification of different
histologic subtypes of ovarian cancers based on TIL and
PD-L1 revealed that type I patterns were more common
in high-grade serous cancers while type IV patterns pre-
dominated in other histologic subtypes (Table 2) [18].
Expression of PD-L1 on ovarian cancer cells
Hamanishi and colleagues first reported that high ex-
pression of PD-L1 on ovarian cancer cells was associated
with poorer outcomes [20]. The 5-year survival rate for
patients with high- versus low-expressing PD-L1 tumors
was 52.6 ± 7.7% versus 80.2 ± 8.9%, p = 0.016, respect-
ively. PD-L2 expression was also associated with poorer
Table 1 Classification of tumors based on presence of tumor
infiltrating lymphocytes (TIL) and PD-L1 expression (based on
Teng et al. [9])
Type I: Adaptive immune resistance
TIL+
PD-L1+
Type II: Immunological ignorance
TIL-
PD-L1-






Table 2 Classification of ovarian cancers by type of immune
microenvironment (based on Webb et al. [18])
% Total for histologic subtype
Histologic subtype N Type I Type II Type III Type IV
High-grade serous 112 57.4 5.1 0 37.4
Low-grade serous 11 0 9.1 0 90.9
Mucinous 30 26.7 16.7 0 56.7
Endometrioid 125 22.4 14.4 1.6 61.6
Clear cell 129 16.2 30.2 0 53.5
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outcomes but was not statistically significant. High ex-
pression of PD-L1 on ovarian cancer cells was associated
with reduced infiltration of cytotoxic T lymphocytes into
tumors suggesting that PD-L1 expression promotes an
immunosuppressive microenvironment by inhibiting T-
cell infiltration [20]. Both PD-L1 expression and TIL
were independent prognostic factors, though PD-L1
expression was inversely correlated with survival. In pre-
clinical models, PD-L1 expression can be induced by
interferon-gamma (often produced by TILs) and admin-
istration of chemotherapy, suggesting a balance that
maintains an immune suppressive environment [21,
22]. PD-1/L1 blockade causes regression of ovarian
tumors in a syngeneic ovarian cancer mouse model
further validating the importance of this regulatory
pathway [23].
PD-L1 expression is not limited to tumor cells and has
been reported on immune cells including antigen-
presenting cells, T-cells, and B-cells. A recent study showed
that PD-L1 expression is predominantly expressed by mac-
rophages in ovarian cancer rather than on the ovarian
cancer cells themselves; in this context, macrophage asso-
ciated PD-L1 expression was a marker of favorable progno-
sis [18]. The differences between this study and the one
above may be due to the differences in the antibodies used,
but also reflect the developing understanding of PD-L1 ex-
pression and its prognostic role in ovarian cancer. PD-L1
expression may be a marker of a tumor poised to respond
to immune stimulatory effects of chemotherapy or perhaps
because PD-L1 may suppress the activity of immune-
suppressive immune cells (i.e. Tregs), PD-L1 expression
on immune cells could tip the balance towards a
more favorable immune microenvironment [24]. Thus
evaluating PD-L1 expression on tumor cells in isola-
tion is not sufficient to predict immune response and
efficacy of immune checkpoint blockade in ovarian
cancer.
Trials of immune checkpoint inhibitors in ovarian cancer
Several antibodies directed against PD-1, PD-L1, and
CTLA-4 have been developed and are being tested clin-
ically in patients with ovarian cancer. Table 3 reflects the
latest data from studies that have reported outcomes.
Table 4 shows ongoing ovarian cancer trials with immune
checkpoint inhibitors as monotherapy or combined with
other agents. The schema for ongoing or planned phase 3
studies are shown in Fig. 2.
Nivolumab
Nivolumab is a fully humanized IgG4 monoclonal anti-
body targeting the PD-1 receptor and is FDA approved
for the treatment of melanoma, NSCLC, renal cell car-
cinoma, and Hodgkin’s lymphoma. A study of nivolumab
in recurrent ovarian cancer was the first to be published
Table 3 Studies of immune checkpoint inhibitors in ovarian cancer with reported results
Immunotherapy
agent(s)




I 9 PR (1; 35+ mos.)
SD (3; 1 for 6+ mos.)
diarrhea Hodi et al. [50]
BMS-936559
(anti-PD-L1)
NCT00729664 recurrent EOC I 17 6% PR (1; 1.3+ mos.)
18% SD (3; 6+ mos.)
infusion-related reaction,
adrenal insufficiency
Brahmer et al. [80]
Nivolumab platinum resistant
EOC
II 20 10% CR (2; 11+ mos.)
5% PR (1; 11+ mos.)
30% SD (6; 1 for 11+ mos.)
lymphocytopenia,
hypoalbuminemia,
elevated ALT, rash, fever, anemia
Hamanishi et al. [25]
Pembrolizumab NCT02054806 recurrent EOC,
PD-L1 positive
Ib 26 4% CR (1; 6+ mos.)
8% PR (2; 6+ mos.)
23% SD (8; 2 for 6+ mos.)
transaminitis Varga et al. [26]
Ipilimumab NCT01611558 recurrent EOC II 40 10% BRR (4; NA) NA clinicaltrials.gov [27]
Avelumab NCT01772004 recurrent EOC Ib 124 10% PR (12; 4 for
6+ mos.) 44%
SD (55; NA)
rash, edema, elevated amylase/
lipase, arthritis, colitis,
hyperglycemia/DM
Disis et al. [28]
Durvalumab
+ Olaparib
NCT02484404a recurrent EOC I/II 10 PR (1; 11+ mos.)
SD (7; 4+ mos.)
Lymphopenia, anemia Lee et al. [29]
Durvalumab
+ Cediranib
4 PR (1; 7 mos.)





Abbreviations: N number of ovarian cancer patients treated, EOC epithelial ovarian cancer, CR complete response, PR partial response, SD stable disease, ALT
alanine aminotransferase, BRR best response rate (CR/PR status not provided), mos. months, NA not available, DM diabetes mellitus; PE, pulmonary embolism
aAs of data cut-off date: May 10, 2016
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Table 4 Ongoing studies of immune checkpoint inhibitors in ovarian cancer
Phase Trial number Trial Disease status Immunotherapy
agent(s)
Concurrent therapy
3 NCT02580058 A Study Of Avelumab Alone Or In Combination
With Pegylated Liposomal Doxorubicin Versus
Pegylated Liposomal Doxorubicin Alone In
Patients With Platinum Resistant/Refractory




3 NCT02718417 Avelumab in Previously Untreated Patients With
Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
primary Avelumab Carboplatin Paclitaxel
3 ENGOT-ov29-
GCIG
A randomized, double-blinded, phase III study of
atezolizumab versus placebo in patients with late
relapse of epithelial ovarian, fallopian tube, or







2 NCT02440425 Dose Dense Paclitaxel With Pembrolizumab
(MK-3475) in Platinum Resistant Ovarian Cancer
recurrent platinum
resistant
Pembrolizumab Dose Dense Paclitaxel
2 NCT02498600 Nivolumab With or Without Ipilimumab in Treating
Patients With Persistent or Recurrent Epithelial





2 NCT02520154 Pembrolizumab in Combination With Chemotherapy
in Frontline Ovarian Cancer
primary Pembrolizumab Carboplatin Paclitaxel
2 NCT02659384 Anti-programmed Cell Death-1 Ligand 1 (aPDL-1)
Antibody Atezolizumab, Bevacizumab and






2 NCT02674061 Efficacy and Safety Study of Pembrolizumab





2 NCT02764333 TPIV200/huFR-1 (A Multi-Epitope Anti-Folate
Receptor Vaccine) Plus Anti-PD-L1 MEDI4736











1/2 NCT02431559 A Phase 1/2 Study of Motolimod (VTX-2337) and
MEDI4736 in Subjects With Recurrent, Platinum-
Resistant Ovarian Cancer for Whom Pegylated





1/2 NCT02484404 Phase 1 and 2 Study of MEDI4736 in Combination
With Olaparib or Cediranib for Advanced Solid
Tumors and Recurrent Ovarian Cancer
recurrent platinum
sensitive/resistant
Durvalumab Olaparib or Cediranib
1/2 NCT02485990 Study of Tremelimumab Alone or Combined With
Olaparib for Patients With Persistent EOC (Epithelial
Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
recurrent or persistent Tremelimumab Olaparib






1/2 NCT02657889 Study of Niraparib in Combination With Pembrolizumab
(MK-3475) in Patients With Triple-negative Breast Cancer




1/2 NCT02726997 Matched Paired Pharmacodynamics and Feasibility
Study of Durvalumab in Combination With
Chemotherapy in Frontline Ovarian Cancer
primary Durvalumab Carboplatin Paclitaxel
1 NCT02737787 A Study of WT1 Vaccine and Nivolumab For Recurrent
Ovarian Cancer
≥2nd remission Nivolumab WT1 vaccine
0 NCT02728830 A Study of Pembrolizumab on the Tumoral
Immunoprofile of Gynecologic Cancers
primary Pembrolizumab
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for this patient population [25]. In this study 20 patients
with platinum-resistant ovarian cancer were treated in 2
cohorts either with 1 or 3 mg/kg nivolumab every
2 weeks until progression or up to 48 weeks. Best overall
response was the primary endpoint. Grade 3 or 4 ad-
verse events occurred in 8 patients (20%) and two expe-
rienced severe adverse events (grade 3 disorientation,
gait disorder, fever in 1 patient and grade 3 fever, deep
venous thrombosis in the other). The best overall re-
sponse was 15%. Four patients experienced prolonged
disease control (2 patients in each dose cohort) with 2
patients in the 3 mg/kg cohort experiencing a durable
complete response (CR). While response rates were
similar to what has been seen with chemotherapy in
platinum resistant disease, the durable responses are
atypical in this disease and a cause for enthusiasm par-
ticularly in a very heavily pre-treated population. PD-L1
expression did not significantly correlate with objective
response. Fourteen of 16 patients with PD-L1 high ex-
pression did not show a response while 1 of 4 patients
with low expression was a responder.
Pembrolizumab
Pembrolizumab is an anti-PD-1 humanized IgG4 mono-
clonal antibody FDA-approved for the treatment of
melanoma and NSCLC. A non-randomized, multicohort
phase Ib study (KEYNOTE-028, NCT02054806) was
conducted of single-agent pembrolizumab in ovarian
cancer patients [26]. Eligibility requirements included
expression of PD-L1 in 1% of tumor nests or PD-L1 ex-
pression in stroma. Pembrolizumab 10 mg/kg was given
every 2 weeks until progression, intolerable adverse ef-
fects or for up to 2 years. Twenty-six patients were
treated. Objective response rate was 11.5% with 1 CR, 2
partial responses (PR), and 23% stable disease (SD).
Durable responses were noted and the median time to
response was 8 weeks.
Ipilimumab
Ipilimumab is a recombinant, IgG1 human monoclonal
antibody targeting CTLA-4 that is FDA-approved for
the treatment of melanoma. In a phase II study of ipili-
mumab monotherapy in recurrent platinum-sensitive
ovarian cancer (NCT01611558), 40 patients were treated
with 10 mg/kg ipilimumab every 3 weeks x 4 doses (in-
duction phase) followed by 10 mg/kg every 12 weeks
until progression or unacceptable toxicity [27]. Of the 40
who started the study, 38 (95%) did not complete the in-
duction phase because of disease progression (14, 35%),
drug toxicity (17, 42.5%), death (1, 2.5%), or other/unre-
ported (6, 15%). Twenty patients (50%) experienced
drug-related adverse events of grade 3 or higher. The
Fig. 2 Ongoing or planned phase 3 trials in ovarian cancer with immune checkpoint inhibitors. a NCT02718417: Javelin Ovarian 100.
b ENGOT-ov29-GCIG: ATALANTE. c NCT02580058: Javelin Ovarian 200. d NRG-GY009
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objective response rate (ORR) was 10.3% [95% confidence
interval (CI) 2.9 to 34.2%] by RECIST criteria. Of note, the
10 mg/kg dose is higher than the FDA approved dose for
the treatment of unresectable or metastatic melanoma
(3 mg/kg) but is equivalent to the dose used for the adju-
vant treatment of melanoma.
Avelumab
Avelumab is a fully humanized monoclonal anti-PD-L1
IgG1 antibody that does not block PD-1 interaction with
PD-L2. In a Phase Ib (NCT01772004, Javelin solid tumor
study) [28], 124 patients with refractory or recurrent
ovarian cancer (progression within 6 months, or after
2nd/3rd line treatment) were treated with 10 mg/kg every
2 weeks until progression or unacceptable toxicity. The
median duration of treatment was 12 weeks. Grade 3/4
adverse events occurred in 6.4% of patients and 8.1% of
patients discontinued treatment secondary to an adverse
event. Twelve patients experienced a partial response for
an ORR of 9.7%. Disease control rate (DCR, defined as
ORR + SD) was 54%. ORR was 12.3% in PD-L1+ tumors
and 5.9% in PD-L1- tumors (based on > =1% threshold).
Differences in median PFS and OS were not statistically
significant based on PD-L1 expression. There are currently
two Phase 3 trials of avelumab for ovarian cancer; one for
front-line therapy in combination with carboplatin and
paclitaxel (Javelin ovarian 100) and the other for recurrent
platinum-resistant disease (Javelin ovarian 200) (Fig. 2).
Durvalumab
Durvalumab is an Fc optimized IgG1 monoclonal anti-
body directed against PD-L1, recently given breakthrough
therapy designation by the FDA for PD-L1 positive
urothelial bladder cancer. In an ongoing phase I/II study
of durvalumab (NCT02484404) in combination with ei-
ther the PARP inhibitor, olaparib, or the VEGFR inhibitor,
cediranib, there was 1 PR in 9 evaluable ovarian cancer
patients lasting >6 months with the combination of durva-
lumab and olaparib and 1 PR in 5 evaluable ovarian cancer
patients treated with durvalumab and cediranib [29].
Other immune checkpoint inhibitors
Atezolizumab is an Fc-engineered, humanized, non-
glycosylated IgG1 kappa monoclonal antibody targeting
PD-L1 that is FDA-approved for the treatment of bladder/
urothelial carcinomas. Tremelilumab is a fully humanized
antibody against CTLA-4. To date no studies have re-
ported outcomes for patients with ovarian cancer treated
with atezolizumab or tremelilumab.
Although cross trial comparisons are not feasible given
the early stage of development and different trial eligibil-
ity parameters, it is remarkable that all of the studies so
far have similar ORR (10–15%). This is markedly lower
than was seen in early trials of PD-1 inhibitors for
Hodgkin’s lymphoma where >65% of patients had a re-
sponse to treatment and 17–21% achieved a complete
response [30, 31], but more consistent with response
rates in previously treated patients with melanoma
(28%), NSCLC (18%), and renal cell carcinoma (27%)
[32]. The phase Ib avelumab study suggests that ovarian
cancer patients who have been treated with fewer prior
courses of chemotherapy may have a greater benefit
from these agents, thus chemotherapy may induce T-cell
exhaustion or have other irreversible immunosuppres-
sive effects [33].
Combining the nivolumab and avelumab studies cited
above, it is notable that 4 of the 5 patients who experi-
enced durable responses had tumors with clear cell hist-
ology [25, 28]. Histology of responding patients on other
studies has not been reported. These observations run
counter to the prediction that ovarian cancers with clear
cell histology would be less likely to respond to PD-1
inhibitors based on low PD-1 expression and low TIL in-
filtration (Table 2). However, they are particularly intri-
guing given the characteristic chemorefractory nature of
ovarian clear cell carcinomas (OCCC) [34, 35]. Because
OCCC are genomically remarkably similar to RCC, it
has been postulated that therapies effective for RCC may
be similarly effective for OCCC [36]. Nivolumab was re-
cently approved for the treatment of advanced RCC based
on the phase III CheckMate 025 trial in which nivolumab
showed an ORR of 25% and a 5 month OS benefit over
everolimus (ORR 5%) [37]. Whether immune checkpoint
inhibitors will result in such dramatic benefits in OCCC
remains to be determined in larger cohorts.
Opportunities to improve outcomes with immune
checkpoint inhibitors
Identification of predictive biomarkers
A critical need in this field is the development of bio-
markers that can predict response to therapy, provide
early indication of efficacy, and warn of the development
of adverse effects. The most promising have focused on
prediction of response to PD-1/L1 therapy. Indications
in melanoma trials that tumor PD-L1 expression, density
of TILs, and proportion of T cells expressing PD-1 or PD-
L1 was associated with response led to the categorization
schema outline above in an attempt to identify subsets of
melanoma patients who would be most likely to respond
to treatment (Table 1) [3, 9]. Further validation is still ne-
cessary to determine whether this categorization predicts
better outcomes. Individually none of these factors is a
reliable predictor of response.
PD-L1 expression and TILs
Several studies of anti-PD-1/L1 therapeutic antibodies in
multiple tumor types, including melanoma and NSCLC,
have suggested that PD-L1 expression is associated with
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a greater likelihood of benefit [8, 32, 38–40]. These stud-
ies typically categorized tumors as PD-L1 positive if at
least 5% of tumor cells showed cell-surface PD-L1 stain-
ing. While initial studies suggested that PD-L1 negative
tumors did not show response [32, 38], subsequent studies
in multiple tumor types have shown objective responses
in up to 20% of PD-L1 negative tumors [39, 41, 42]. In
comparison, the phase 2 nivolumab study in ovarian
cancer patients showed that only 2 of 16 patients with
high PD-L1 expression showed a response, while 1 of 4
patients with low expression responded [25]. Similarly,
the avelumab study showed that even with a staining
cut-off level of ≥1% of tumor cells in ovarian cancer, 1
of 17 patients with a PD-L1 negative tumor showed an
objective response [28]. Thus, it is unclear whether PD-
L1 can be used reliably as a predictive biomarker for
anti-PD-1/L1 directed therapy. By contrast, PD-L1 ex-
pression status does not appear to influence response
to anti-CTLA-4 therapy. In a study of previously un-
treated melanoma, median PFS (mPFS) in response to
ipilimumab was unaffected by PD-L1 status (PD-L1
positive 3.9 months, 95% CI 2.8 to 4.2 months versus
PD-L1 negative 2.8 months, 95% CI 2.8 to 3.1 months)
while response to nivolumab was influenced by PD-L1
status (14.0 months, 95% CI 9.1 to not reached versus
5.3 months, 95% CI 2.8 to 7.1 in PD-L1 positive versus
PD-L1 negative tumors, respectively) [43].
Other attempts at identifying predictive biomarkers
have focused on T-cell infiltration. In melanoma, T-cell
density, particularly at the invasive tumor border, has
been associated with response to anti-PD-1 therapy,
however tumors with low T cell density have also shown
response [44]. However, a separate study evaluating fac-
tors associated with response to anti-PD-1 therapy in
multiple solid tumors treated on a phase I clinical trial
showed that the presence of TILs did not correlate with
clinical outcomes [8]. Response to anti-CTLA-4 therapy
has been associated with a more inflamed tumor micro-
environment and potential markers include increased
expression of the activation marker, inducible T-cell co-
stimulator (ICOS), on peripheral blood CD4+ cells and
tumor-infiltrating lymphocytes, and an increase in Teff:-
Treg cell ratio in tumor tissues [45–50]. However no
validated predictive biomarkers for CTLA-4 therapy are
yet available.
Several factors may account for the difficulty in using
receptor expression and T-cell populations as predictive
biomarkers. PD-L1 expression and T-cell infiltration are
dynamic processes so evaluation of tissue archived at the
time of surgery may not reflect the level of expression at
the time of recurrence or planned treatment. Small
tumor specimens may miss focal expression of PD-L1 or
T-cells localized only at the leading edge of the tumor.
Scoring of immunohistochemistry for PD-L1 and TILs
has not yet been standardized. Additionally, there are
challenges associated with the use of different anti-
bodies, fixation and staining techniques, and the subject-
ive interpretation of staining thresholds. Added to this
complexity is defining the importance of the subset of
cells (immune versus tumor) upon which PD-L1 is
expressed. At this point, there is no indication that PD-
L1 expression or TIL by IHC should be used as an abso-
lute selection criterion for therapy.
Mutational load
Genetic alterations within a tumor (including mutations,
DNA rearrangements, deletions, and insertions) have the
potential to generate neo-antigens which are associated
with clinical response to immune checkpoint therapies.
Tumors with higher mutational loads, such as melan-
oma, NSCLC, and bladder cancer, have shown the great-
est response rates to anti-PD-1/PD-L1 therapy, while
cancers with relatively low mutation rates (pancreatic
and prostate cancers) have shown low response to these
therapies [51]. In melanoma, mutational load was associ-
ated with the degree of clinical benefit to CTLA-4 block-
ade and pembrolizumab [52–54]. However, there are
patients with low mutational burden who have responded
and those with high mutational burden that have not and
no specific cut-off point could be determined under which
patients would not derive benefit [54].
Mismatched repair (MMR) deficiency, defined by de-
fects in one or more of 6 genes involved in the DNA
mismatch repair complex, results in 10–100 fold in-
creases in tumor mutational burden compared to MMR-
competent tumors. MSI tumors express high levels of
multiple immune checkpoint molecules including PD-1,
PD-L1, CTLA-4 and lymphocyte activation gene 3
(LAG3) [55]. Le et al. showed that MSI-high status in
colorectal cancer and mismatch-repair deficient non-
colorectal cancers was able to predict clinical response
to pembrolizumab in a phase 2 trial [56, 57]. There was
an ORR of 48% across tumor histologies with 12 month
OS and PFS rates of 79 and 54%, respectively. Germline
MMR gene inactivation only occurs in ~2% of ovarian
cancers, however somatic loss of expression can occur in
up to 29% of ovarian cancers [58]. Whether microsatel-
lite instability status (MSI) status may be a predictive
biomarker to identify genetic subsets of ovarian tumors
with an improved likelihood of response to immune
checkpoint inhibition remains to be determined.
In non-MMR deficient ovarian cancers, the predomin-
ant genetic abnormality is copy number alteration and
mutation rate is generally low [59]. Despite relatively
low mutation burdens compared to other cancers, in-
creased neo-antigen presentation may result from other
genetic alterations. Patients with BRCA-associated tu-
mors may be more likely to have a higher burden of
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genetic alterations (copy number alterations, deletions,
amplifications) given the role of BRCA in homologous
recombination DNA repair [60]. BRCA1-associated
ovarian cancers have also been associated with increased
intra-tumoral T-cell infiltration [61]. Thus it has been
suggested that these patients may derive greater benefit
from immune checkpoint inhibitors. Contrary to this hy-
pothesis, no responses were seen in patients with a
BRCA mutation in the avelumab phase Ib study (ORR
16% in BRCA-wildtype tumors), DCR was 11.1% in
BRCA-mutation carriers versus 48.0% in BRCA-wildtype
[28]. Thus at this time, there is no reason to suggest that
immunotherapy trials should be limited to this patient
population, beyond the stated objective of the study.
Functional assays
Other approaches to developing predictive biomarkers
include assessing functional capacity of the immune
cells within the tumor microenvironment. These ap-
proaches include intracellular cytokine staining to
measure interferon-gamma signaling and T-cell poly-
functionality, measurement of local inhibitory cytokine
production (IL-10, TGF-beta), measurement of T-cell
activation or proliferation potential, and T-cell clonal-
ity/repertoire [62–69]. However, as of yet, none of
these approaches has been validated to be predictive of
response to therapy.
Combinatorial therapy to improve therapeutic outcomes
Improved therapeutic efficacy has been demonstrated
with the combination of anti-PD-1 and anti-CTLA-4
inhibitors. In previously untreated melanoma patients,
median PFS was 11.5 months (95% CI 8.9–16.7 months)
with nivolumab and ipilimumab compared with
2.9 months (95% CI 2.8–3.4) with ipilimumab and
6.9 months (95% CI 4.3 to 9.5) with nivolumab alone
[43]. Interestingly, in patients whose tumors did not ex-
press PD-1, median PFS was improved in patients re-
ceiving both drugs compared to those who received
nivolumab alone; there was no difference in median PFS
between these two treatment groups in patients with
PD-1 expressing tumors. The frequency of treatment re-
lated toxicities was also increased with combination
therapy; 55% of patients experienced grade 3/4 events in
the nivolumab and ipilimumab group, 16.3% in the nivo-
lumab group, and 27.3% in the ipilimumab group. In
mouse models of ovarian cancer, 1/3 to 1/2 of TILs
coexpressed PD-1 and CTLA-4 [70]. This subpopulation
exhibited poor effector functions with diminished cap-
acity to secrete effector cytokines and proliferate. Dual
blockade of PD-1 and CTLA-4 increased T-cell activity
and tumor regression. This treatment strategy is cur-
rently being evaluated for recurrent ovarian cancer in
the NRG Oncology study GY003 (NCT02498600).
Similarly, combining immune checkpoint inhibitors
with other anti-neoplastic treatments to enhance thera-
peutic outcomes is an active area of investigation (see
Table 4 for trials for ovarian cancer). Chemotherapy,
radiotherapy, tyrosine kinase inhibitors, and epigenetic
modulators may be synergistic adjuncts to immunother-
apy through their ability to increase tumor immunogen-
icity [71–74]. A particular area of interest for ovarian
cancer is the combination of immune checkpoint inhibi-
tors with anti-angiogenic agents and/or PARP inhibitors.
Both anti-angiogenic agents and PARP inhibitors influ-
ence the ovarian cancer immune microenvironment in in
vivo models and combination therapy is supported by pre-
clinical studies [75–78]. Clinical trials of combination
therapy are ongoing, so far phase I results of durvalumab/
cediranib and durvalumab/olaparib (NCT02484404) show
the combinations are feasible. It will be necessary to
develop individualized approaches to determine which
treatment strategy is most likely to be effective for in-
dividual patients.
Management considerations with immune checkpoint
inhibitors
Immune-related toxicities
Related to their mechanism of action of impairing T-cell
inhibition, immune checkpoint inhibitors can cause a
loss of self-tolerance and thus the development of
immune-related adverse effects (irAEs). While the fre-
quency of irAEs with these agents is common (~60%
with anti-CTLA-4 therapy and 40% with anti-PD-1/L1
therapy), in general serious toxicity [grade 3–5 using the
Common Terminology Criteria for Adverse Events
(CTCAE)] is more likely with anti-CTLA-4 therapy
(>40%) than with anti-PD-1/L1 therapy (~5%) [32, 79, 80].
While the immune side effects could involve any organ
system, the most common irAEs with both anti-CTLA-4
and anti-PD-1/L1 therapy are dermatologic (rash, pruri-
tis), gastrointestinal (diarrhea), rheumatologic (arthralgia,
arthritis, myalgia, myositis), endocrine disorders (thyroid-
itis, hypothyroidism, hypophysitis), and infusion-related
reactions. Serious gastrointestinal toxicities, such as
immune-mediated colitis and hepatitis, are more likely
with anti-CTLA-4 therapy. Involvement of the following
organ systems is much less common, especially with
anti-PD-1/L1 pathways inhibitors, but have been ob-
served including: pulmonary (pneumonitis, sarcoidosis),
hematologic (hemolytic anemia, aplastic anemia, neutro-
penia), ocular (uveitis, conjunctivitis), cardiac (myocardi-
tis, pericarditis), neurologic (myasthenia gravis, Guillan
Barre, Bell’s palsy, posterior reversible leukoencephalopa-
thy, and aseptic meningitis). While irAEs associated with
these therapies are generally reversible, without prompt
management they can evolve into life-threatening condi-
tions. Early recognition of the development of these events
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is critical to prevention of the progression to severe ad-
verse effects. Vigilance, both on the part of the patient and
the treating physician, is necessary to identify subtle devel-
oping signs of irAEs and specialty consultation may be ne-
cessary when irAEs are suspected but not definitive.
Immune-related AEs can develop at any time during treat-
ment and even after discontinuation of therapy. However,
the onset of irAEs follows a characteristic pattern of devel-
opment. For the CTLA-4 inhibitor, ipilimumab, most
irAEs develop during the initial induction period (usually
4 doses given every 3 weeks). Dermatologic reactions
more commonly occur early during treatment, frequently
during the first few weeks, while diarrhea and colitis
develop later. Endocrine disorders may be late effects,
frequently developing between 7 and 20 weeks after
initiation of treatment and sometimes being identified
after discontinuation of treatment [81]. Combining
CTLA-4 inhibitor and PD-1 inhibitors, while signifi-
cantly increasing response also results in substantially
more irAEs.
Spain et al. recently provided a substantive review of
the management of irAEs [82]. Briefly, management is
dependent on the severity of the event, usually graded
using CTCAE. All references to grade in this article will
be using CTCAE version 4.0 [83]. Typically grade 1
symptoms can be monitored and may not require inter-
ruption of therapy. For Grade 2 symptoms, the immune
checkpoint inhibitor therapy should be withheld until
symptoms improve and treatment with an immunomod-
ulatory medication may be considered. Immune-related
AEs with a higher risk of resulting in serious organ dys-
function (such as colitis, hepatitis, pneumonitis, nephritis,
neurologic symptoms) likely warrant initiation of cortico-
steroid treatment early (Grade 2) rather than waiting for
symptoms to worsen. When the severity of the irAE war-
rants the reversal of inflammation (≥ Grade 3), corticoste-
roids are the first immunomodulatory medication to be
administered. Careful and timely monitoring of response
to steroid therapy is required to identify steroid-refractory
cases. In these situations, the use of more potent im-
munomodulatory agents may be necessary such as the
anti-TNF-alpha antibody infliximab, the anti-metabolite
mycophenylate mofetil, anti-thymocyte globulin, and/or
calcineurin inhibitors (i.e. tacrolimus and cyclosporine).
Consultation with, and if indicated hospitalization at, a
center familiar with steroid-refractory immune checkpoint
inhibitor irAEs is advised.
Steroid use during treatment
Because of the effect of steroids on inhibiting T-cell
activation, patients receiving supraphysiologic doses of
corticosteroids have generally been excluded from trials
of immune checkpoint inhibitors. In the most compre-
hensive retrospective review on the subject, Horvat et al.
evaluated the effect of initiation of immunomodulatory
agents for ipilimumab irAEs in melanoma patients [84].
Of the 298 patients, 85% experienced an irAE of any
grade, 35% required corticosteroid treatment, and 10%
required anti-TNFalpha therapy. Overall survival and
time to treatment failure (median 5.7 months) was not
affected by the occurrence of irAEs or the use of sys-
temic corticosteroids. Continued anti-tumor activity has
been observed in patients treated with high-dose ste-
roids for irAEs [85]. However, data on the effects of ster-
oid use on immune checkpoint inhibitor efficacy are still
limited. Thus, it is recommended to avoid prophylactic
steroids and limit therapeutic steroids as needed.
Measurement of response: specific immune related criteria
One of the challenges faced in assessing the therapeutic
value of these agents is determining the most appropri-
ate measurement of efficacy. While response rates to im-
mune checkpoint inhibitors as single agents is relatively
low, the impressive duration in responding patients
suggests that overall survival may be a better measure of
efficacy. In fact, there have been patients who achieve
long-term survival benefit without evidence of clinical
response [53]. In addition, early studies noted that some
patients had responses after initial apparent progression
of disease, while others showed a mixed response or new
lesions despite an overall decrease in tumor burden.
Since these response patterns were not adequately
captured by RECIST1.1, new immune-related response
criteria (irRC) were developed to specifically accommo-
date the response patterns seen after treatment with im-
mune checkpoint inhibitors [86]. Unlike in RECIST1.1,
new lesions do not automatically signal progression and
apparent progressive disease must be confirmed 4 weeks
after initial assessment to qualify for true progression. In
melanoma patients treated with either ipilimumab or
pembrolizumab, ‘pseudoprogression’ occurred in ~ 7% of
patients and has been attributed to peritumoral lympho-
cyte infiltration or delayed immune activity [87–89].
RECIST1.1 was noted to underestimate the benefit of
pembrolizumab in this population by up to 15% [88].
However, because this phenomenon occurs relatively in-
frequently, many studies continue to use RECIST1.1. In
order to adequately assess efficacy across studies, it will
be necessary to harmonize response assessments across
studies and identify more refined radiographic or bio-
logic markers of early efficacy. In addition, the develop-
ment of other immune-specific clinical trial endpoints
may be necessary to account for prolonged duration of
response after initial progression [90].
Rates of pseudoprogression in ovarian cancer have not
been reported, but trials to date suggest it occurs less
frequently than in melanoma [25, 26, 28]. Thus, in con-
trast to the management of melanoma, progression by
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RECIST1.1 is likely true tumor progression. While treat-
ment beyond progression is sometimes considered in
melanoma patients until true progression is confirmed,
further treatment after progression in ovarian cancer pa-
tients may carry additional risks as peritoneal implants
could progress to cause bowel obstruction.
Conclusions
The advent of immune checkpoint inhibitors has stimu-
lated increased enthusiasm for immune-oncology. In
ovarian cancer, while there is compelling data that the
immune microenvironment influences outcomes, early re-
sults of clinical trials of immune checkpoint inhibitors
suggest limited tumor response. Strategies to improve
treatment outcomes and minimize immune-related toxic-
ities are necessary and will likely require individualized
approaches. There are multiple areas in which the cancer-
immune system interaction can fail to result in adequate
anti-tumor activity. To better understand these areas, the
development of biomarkers to determine those therapies
active in an individual tumors, so called ‘personalized im-
munotherapy’, are critical. Some have suggested the use of
the “cancer immunogram” to describe individual tumor:-
immune system interactions [91]. Biomarker guided clin-
ical trials will be necessary to tailor these approaches to
ovarian cancer patients. We anticipate that tumor gen-
omic profiling will need to be integrated with immune
profiling to provide a more comprehensive understanding
of an individual patient’s tumor leading to improved treat-
ment selection and sequencing.
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